News

A predictive tool that incorporates several blood biomarkers may help to identify primary biliary cholangitis (PBC) patients who are less likely to respond to treatment…

A genetic variant unique to East Asians increases the risk of intrahepatic cholestasis of pregnancy (ICP) by more than 16 times, but it likely…

Daily treatment with the investigational oral therapy lanifibranor — used alone or in combination with the diabetes medication Jardiance (empagliflozin) — led to improvements…

Children with biliary atresia who received infusions of bone-marrow stem cells during a Kasai operation, a liver surgery that’s the main strategy for treating…

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to brelovitug, a hepatitis D treatment that’s being developed by Bluejay…

Gilead Sciences’ Livdelzi (seladelpar) has been approved in the U.K. as a treatment for adults with primary biliary cholangitis (PBC), either in combination…

In real-world use, Kayfanda (odevixibat) — available under the brand name Bylvay in the U.S. — lowered blood bile acid levels and eased…

Alagille syndrome comes with a high clinical, economic, and quality-of-life burden for patients and their families, but new treatments such as Livmarli (maralixibat)…

Virion Therapeutics has announced that it’s completed enrollment for the first two groups of adults with chronic hepatitis B virus (HBV) infection in…

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to CNP-104, Cour Pharmaceuticals’ treatment candidate for primary biliary cholangitis (PBC).